A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

Phase 3

Terminated

• Conditions: Asthma
• Interventions: Drug: levalbuterol tartrate HFA inhalation aerosol; Drug: placebo

• Registration Number: NCT02150499
• Lead Sponsor: Sumitomo Pharma America, Inc.

Brief Summary

This is a study of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who go to the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.

Detailed Description

This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to ≤ 48 months of age with acute bronchospasm. It is a randomized, double-blind, parallel-group, multicenter, trial of 3 doses of levalbuterol tartrate HFA inhalation aerosol MDI in pediatric subjects birth to ≤ 48 months of age who present to either the Emergency Department (ED) or their physician's office with an acute bronchospasm. Subjects presenting to the ED or physician's office with an acute bronchospasm must have a history of reactive airways disease, based on subjects' parent/guardian report.

Eligible subjects whose parent(s) or legal guardian(s) provide written informed consent to participate will be randomized to 1 of 2 treatments. Treatment 1 consists of 3 doses, with each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA \[cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol\]); Treatment 2 consists of 3 doses, with each dose comprised of 8 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff \[cumulative dose of 1080 mcg of levalbuterol tartrate HFA inhalation aerosol\]). For each Treatment, study medication will be administered every 20 minutes over a period of 1 hour for three doses.

Study Timeline

• Study First Submitted: 2014-05-27
• Study First Submitted QC: 2014-05-27
• Study First Posted: 2014-05-30
• Study Start: 2014-07
• Primary Completion: 2014-12
• Study Completion: 2014-12
• Results First Submitted: 2015-11-18
• Results First Submitted QC: 2016-01-04
• Results First Posted: 2016-02-03
• Status Verified: 2016-03
• Last Update Submitted: 2016-03-10
• Last Update Posted: 2016-04-08

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Male or female from birth to 48 months of age, inclusive, whose parent(s) or legal guardian(s) provide written informed consent prior to study participation and are willing to comply with study procedures.
2. Subject experiencing acute bronchospasm requiring a bronchodilator and who have a history of wheezing.

Exclusion Criteria

1. Subject with a severe illness that, in the opinion of the Investigator, could jeopardize subject safety.
2. Subject received ≥ 8 puffs (MDI) of a beta-2 agonist or 2.5 mg of nebulized levalbuterol, or albuterol 5.0 mg within 4 hours prior to ED or physician's office admittance.
3. Subject received ipratropium within 4 hours prior to ED or physician's office admittance.
4. Subject who participated in an investigational drug study within 30 days prior to enrollment, or who previously participated in the current study.
5. Subject with a known sensitivity to levalbuterol or racemic albuterol or any of the excipients contained in any of these formulations.
6. Subject using any prescription drug (including beta-blockers) with which levalbuterol or racemic albuterol sulfate administration is contraindicated.
7. Subject with a history of clinically significant abnormalities that could interfere with the metabolism or excretion of the study medication (eg, renal, hepatic, metabolic, or endocrine abnormalities).
8. Subject with a history of cancer.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
levalbuterol tartrate HFA inhalation aerosol plus placebo HFA	placebo	Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
levalbuterol tartrate HFA inhalation aerosol plus placebo HFA	levalbuterol tartrate HFA inhalation aerosol	Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
levalbuterol tartrate HFA inhalation aerosol plus levalbuterol	levalbuterol tartrate HFA inhalation aerosol	Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.

Primary Outcome Measures

Name	Time	Method
The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events.	Week 1	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Serious Adverse Events.	Week 1	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events Leading to Discontinuation.	Week 1	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Pulmonary Score (Total Score) to End of Treatment	Day 1	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Change From Baseline in Pulmonary Score (Individual Component Scores) to End of Treatment	Day 1	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Change From Baseline in Pulmonary Score (Total Score) After Each Dose	20 minutes, 40 minutes, 60 minutes	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Change From Baseline in Pulmonary Score (Individual Component Scores) After Each Dose	20 minutes, 40 minutes, 60 minutes	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.
Number and Percentage of Subjects Determined to be Stabilized After Treatment	Day 1	Due to early termination of the study, insufficient data were available to perform the statistical analyses described in the protocol. Only subject listings of disposition, demographics, medical history and safety data were provided.

Trial Locations

Locations (17)

Willis-Knighton Physician Network / Portico Pediatrics; 🇺🇸 Shreveport, Louisiana, United States

Capital Pediatrics & Adolescent Center PLLC; 🇺🇸 Raleigh, North Carolina, United States

Capitol Pediatric & Adolescent Center PLLC; 🇺🇸 Raleigh, North Carolina, United States

Northern Illinois Associates; 🇺🇸 Dekalb, Illinois, United States

Score Physician Alliance, LLC; 🇺🇸 Saint Petersburg, Florida, United States

St. Peter's University Hospital; 🇺🇸 New Brunswick, New Jersey, United States

Michael W. Simon, MD, PSC; 🇺🇸 Nicholasville, Kentucky, United States

Northern Illinios Research Associates; 🇺🇸 Dekalb, Illinois, United States

Craig Spiegel, MD; 🇺🇸 Bridgeton, Missouri, United States

Mid Michigan Sleep Center; 🇺🇸 Grand Blanc, Michigan, United States

Dayton Clinical Research; 🇺🇸 Dayton, Ohio, United States

TTS Research; 🇺🇸 Boerne, Texas, United States

Allergy Asthma Research Institute; 🇺🇸 Waco, Texas, United States

Holston Medical Group; 🇺🇸 Kingsport, Tennessee, United States

PI-Coor Clinical Research; 🇺🇸 Burke, Virginia, United States

Advanced Pediatrics; 🇺🇸 Vienna, Virginia, United States

Charleston Allergy & Asthma Research; 🇺🇸 Summerville, South Carolina, United States